FOXO3 and cardiovascular disorder: Actually, Tanshinol used as a principal active ingredient of approved drug for the treatment of cardiovascular diseases for ten years in China, further studies will be needed to investigate whether it may be a candidate for prevention and therapeutic applications in osteoporosis through manipulation of the Wnt/FoxO3a pathway in bone tissue.